Who Needs Gastroprotection in 2020?

Kanno, Takeshi; Martin, Paul

doi:10.1007/s11938-020-00316-9

Cited by 17 publications

(8 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since there is the possibility that H. pylori eradication fails, in this case the indication to continue PPI treatment should be considered in patients at high risk for PUD complications, such as at increasing age and those who need a long term treatment with gastrolesive drugs such NSAID and for patients taking anticoagulation (Kanno and Moayyedi) [61].…”

Section: Third-line (And Further) Treatmentmentioning

confidence: 99%

Clinical Relevance of Helicobacter pylori Infection

Mladenova¹

2021

JCM

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a Gram-negative helical, microaerophilic bacterium which colonizes the antrum and body of the stomach, surviving in its harsh environment through mechanisms of acid resistance and colonization factors. It infects approximately 50% of the world population. Although the prevalence of this infection varies from country to country, as well as between different ethnic, social or age groups, it is estimated that about 50% of the human population only carries this microorganism. While H. pylori has been found to play a major etiological and pathogenic role in chronic gastritis, peptic ulcer disease and gastric cancer, its importance for many types of extra-gastric disease needs to be further investigated. The choice of tests to diagnose H. pylori infection, defined as invasive or non-invasive, depends on the clinical indication as to whether to perform upper gastrointestinal endoscopy. Focusing on bacterial eradication, the treatment should be decided locally based on the use of antibiotics and documented antibiotic resistance. The author provides an overview of the current state of knowledge about the clinical aspects of H. pylori infection, especially its diagnostic and therapeutic management.

show abstract

Section: Third-line (And Further) Treatmentmentioning

confidence: 99%

Clinical Relevance of Helicobacter pylori Infection

Mladenova¹

2021

JCM

View full text Add to dashboard Cite

show abstract

“…Some of these analogs inhibit COX enzymes and suppress the synthesis of prostaglandin. Although both COX-1 and COX-2 isoforms are involved in homeostatic functions, the gastrointestinal ulceration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been attributed to COX-1 inhibition and subsequent reduction in gastroprotective prostaglandin ( Kanno and Moayyedi, 2020 ). Hence, pyrazole analogs with little or no effect on prostaglandin synthesis and release remain a viable therapeutic option in patients that are highly susceptible to NSAID-induced ulceration.…”

Section: Selected Activitiesmentioning

confidence: 99%

Heterocyclic Compounds: Pharmacology of Pyrazole Analogs From Rational Structural Considerations

et al. 2021

View full text Add to dashboard Cite

Low quality of life and life-threatening conditions often demand pharmacological screening of lead compounds. A spectrum of pharmacological activities has been attributed to pyrazole analogs. The substitution, replacement, or removal of functional groups on a pyrazole ring appears consistent with diverse molecular interactions, efficacy, and potency of these analogs. This mini-review explores cytotoxic, cytoprotective, antinociceptive, anti-inflammatory, and antidepressant activities of some pyrazole analogs to advance structure-related pharmacological profiles and rational design of new analogs. Numerous interactions of these derivatives at their targets could impact future research considerations and prospects while offering opportunities for optimizing therapeutic activity with fewer adverse effects.

show abstract

“…29 They are potentially lifesaving in prevention of gastrointestinal bleeding in patients on aspirin, non-steroidal anti-inflammatory drugs, and anticoagulants, are still the drug of choice in treating acute peptic ulcer disease and for ulcer prophylaxis to reduce the risk of gastrointestinal bleeding in critical care units. 30 Recent guidelines highlight success of PPIs in the treatment of non-ulcer dyspepsia. 31 When used according to appropriate clinical indication and in keeping with guidelines for use, the safety profile of PPIs is excellent, arguably safer than any drug class we use.…”

Section: Benefits Of Proton Pump Inhibitors: Prosmentioning

confidence: 99%

Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between

Sloan

Katz

2021

Foregut

View full text Add to dashboard Cite

The medical and lay literature has exploded with reports of adverse events associated with proton pump inhibitors over the last 10 to 15 years. The dissemination of these reports to patients and clinicians have created substantial concerns regarding what has been an exceptionally valuable drug class, dramatically improving patient quality of life, and in many cases preventing life threatening side effects of other medication. Patients are more frequently seeking to avoid these medications, and practitioners are reducing or discontinuing them to the patient’s detriment due to a misunderstanding of the data. This review will discuss the data regarding the most commonly publicized adverse events and attempt to put them in perspective.

show abstract

Who Needs Gastroprotection in 2020?

Cited by 17 publications

References 130 publications

Clinical Relevance of Helicobacter pylori Infection

Clinical Relevance of Helicobacter pylori Infection

Heterocyclic Compounds: Pharmacology of Pyrazole Analogs From Rational Structural Considerations

Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between

Contact Info

Product

Resources

About